News

LNC aims to develop the first Christensenella-based drug candidate for the treatment of obesity and metabolic disorders Bordeaux, October 15th, 2018 – LNC Therapeutics, a French biotech company specializing in gut microbiome-based drug discovery, today announced that it has signed an exclusive license agreement with Cornell University (Ithaca,...

+ Find out more

Bordeaux, October 1st, 2018 – LNC Therapeutics, a French biotech company specialized in the gut microbiome-based drug discovery, today announced the launch of a new clinical trial with Stablor®, OBEMINALE 2, and the treatment of the first patient. This new clinical study is intended to obtain 13.5 health claim from the European Food...

+ Find out more

LNC Therapeutics, a French biotechnology company specialized in research and development for gut microbiome-based drugs, is putting greater focus on its research on a new cluster of bacteria, christensenella, and its role in regulating the intestinal microbiome in various chronic metabolic diseases. LNC Therapeutics is the first company worldwide to...

+ Find out more

After €6.5 million of fundraising and the arrival of a new Chief Scientific Officer in 2017, LNC Therapeutics today appoints a new CEO and strengthens its microbiome development ambitions Bordeaux (France), April 17, 2018 – LNC Therapeutics, a French biotech company specialized in research and development for gut microbiome-based drugs,...

+ Find out more

Cardiometabolic research specialist announces Sandrine Claus appointment as Chief Scientific Officer to lead its microbiota-oriented ambitious strategy Bordeaux (France), 27th September 2017 – LNC Therapeutics, a company specialized in the research and development of gut microbiota directed drugs for the treatment of obesity and associated...

+ Find out more